MiMedx Group, Inc. provides revenue guidance for the financial year 2022. For the period, the company expects annual revenue growth of 11% to 14% in the Company's continuing portfolio of products.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.29 USD | +2.11% | -2.33% | -28.28% |
Mar. 27 | MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products | MT |
Mar. 27 | MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.28% | 905M | |
-21.76% | 130M | |
-18.62% | 59.78M | |
+0.68% | 58.78M | |
-2.40% | 50.16M |
- Stock Market
- Equities
- MDXG Stock
- News MiMedx Group, Inc.
- MiMedx Group, Inc. Provides Revenue Guidance for the Financial Year 2022